Clozapine-related neutropenia and agranulocytosis in Korea: 2025 update for rethinking the role of monitoring system [0.03%]
韩国氯氮平所致中性粒细胞减少症和粒细胞缺乏症的2025年更新：重新思考监测系统的作用
Nuree Kang,Ji Seon Jang,Sung Woo Joo et al.
Nuree Kang et al.
Background: In February 2025, the FDA ended the mandatory Risk Evaluation and Mitigation Strategy requirements for clozapine. Korea continues mandatory hematologic testing under the Clozapine Patient Monitoring System (CP...
Maura DiSalvo,Joseph Biederman,Hannah O&#x;Connor et al.
Maura DiSalvo et al.
Background: Attention-deficit/hyperactivity disorder (ADHD) is a disorder marked by inattentiveness and/or hyperactivity and increased impulsivity. A common treatment for ADHD is stimulant medications, with a formulation ...
MicroRNAs in metabolic effects with atypical antipsychotics-a scoping review [0.03%]
与非典型抗精神病药物的代谢作用相关的微小核糖核酸-综述性研究
Weng Tong Wu,Deonna Setiawan,Stephen J Glatt et al.
Weng Tong Wu et al.
Background: Metabolic side effects associated with atypical antipsychotics represent a major challenge in the clinical management of schizophrenia, contributing to poor treatment adherence and an increased risk of relapse...
Effects of cariprazine on cholesterol, glucose, and weight in patients with schizophrenia: a systematic review and meta-analysis [0.03%]
卡利拉嗪对精神分裂症患者胆固醇、血糖和体重影响的系统评价和meta分析
Isabella Berardelli,Mariarosaria Cifrodelli,Attilio Valerio Mammoliti et al.
Isabella Berardelli et al.
Background: Cariprazine is a second-generation antipsychotic approved for treating schizophrenia, acute manic or mixed episodes associated with bipolar I disorder, and major depressive disorder. Antipsychotic treatment is...
A scoping review of mystical-type experiences and mood symptom outcomes in psychedelic therapy clinical trials: comparing life-threatening disease and depressive populations [0.03%]
一项范围性审查：迷幻疗法临床试验中的神秘型体验与情绪症状结果：将生命威胁性疾病人群和抑郁症人群进行比较
Ana Deutsch,Luis E Contreras,Sarah Kratina et al.
Ana Deutsch et al.
Background: Psychedelic therapies are gaining attention as tools to alleviate anxiety and depression across various clinical populations. However, the mechanisms behind psychedelics' therapeutic efficacy and the potential...
Clinical hallmarks and peripheral immune factors associated with antipsychotic-induced constipation in schizophrenia [0.03%]
精神分裂症抗精神病药物所致便秘的临床特征及外周免疫因素
Miaomiao Shao,Tingting Zhu,Xiuxiu Hu et al.
Miaomiao Shao et al.
Background: Constipation is a frequent adverse effect of antipsychotic treatment in schizophrenia. Objectives: This study aimed to inve...
Adjunctive xanomeline/trospium in clozapine-resistant schizophrenia: two case reports demonstrating limited response [0.03%]
氯氮平治疗抵抗的精神分裂症患者使用曲潘米奈/屈司匹明作为增效药物：两例病例报告表明有限的疗效响应
Vanessa M Dang,John M Powers,Matej Markota et al.
Vanessa M Dang et al.
Few pharmacologic options exist for patients with clozapine-resistant schizophrenia (CRS) or schizoaffective disorder. Xanomeline/trospium represents a new class of antipsychotic medication that has efficacy as monotherapy for schizophrenia...
A rapid clinical response to etifoxine in treatment-resistant obsessive-compulsive disorder: a case report of a patient with comorbid bipolar disorder [0.03%]
氯羟azino治疗难治性强迫症的快速临床反应——一名合并双相情感障碍患者的病例报告
Pornjira Pariwatcharakul,Punyisa Prachgosin
Pornjira Pariwatcharakul
This case report describes the rapid clinical response to etifoxine, an oral translocator protein 18 kDa (TSPO) ligand, in a patient with severe, treatment-resistant obsessive-compulsive disorder (OCD) with comorbid bipolar I disorder. Desp...
Psychedelic therapy and postpartum depression: priorities and prospects [0.03%]
psychedelia疗法和产后抑郁：优先事项和前景
Guillaume Thuery,Frank Crossen,Daniel Mc Loone et al.
Guillaume Thuery et al.
Approximately 15% of pregnant women experience postpartum depression (PPD). Even with currently available antidepressant treatments, many women will continue to be impaired by symptoms. Psychedelic therapy offers a promising transdiagnostic...
Corrigendum to "Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis" [0.03%]
PTSD药物治疗：系统回顾和元分析的勘误表
[This corrects the article DOI: 10.1177/20451253251342628.]. © The Author(s), 2026.